Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2007

View Archived Issues

Novartis reports pipeline and business highlights of first quarter

Therapeutic autophagy by small-molecule enhancers shows promise for neurodegenerative diseases

Recent Bayer patent describes new treatment option for thrombotic disorders

Recent Pharmaleads and Pfizer patents disclose novel analgesic agents

Novel antimalarial agents disclosed in recent patent literature

Novel arylhydrocarbon receptor antagonist may protect against skin photodamage

Recent Valeant and Medivir patents report novel agents for HIV infection

Gene Logic seeks new development paths for Abbott drugs

Update on Memryte program in Alzheimer's

Phase I findings on S. aureus vaccine

ReNeuron forms collaboration to develop c-mycERstem cell expansion technology

ReAble Therapeutics to acquire Iomed

FDA Advisory Committee votes in favor of ACAM-2000

New phase II trial studies DNB-001 for ocular hypertension

Novartis defends Lotrel patent against Teva generic

Ortho Biotech Products to return BMP-7 program to Curis

Ty-800 typhoid vaccine shows clinical potential

Wex seeks clearance for Canadian study of Tectin

Sun Pharmaceutical to acquire Taro

TRO-19622 begins phase II trial in painful diabetic neuropathy

Towards new additions to the therapeutic armamentarium in psoriasis

Prous Science publishes new report on tuberculosis

FDA approves Velcade + Doxil for relapsed/refractory multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...